This identifies a more general role for a p300/GATA6 axis in cancer and suggests that p300 and GATA6 status can be used to stratify RNF43-mutant pancreatic cancer patients to maximize the clinical benefits of PORCN inhibitors. This evidence concerns the gene PORCN and familial pancreatic carcinoma.